•
Sep 30, 2017

CRISPR Therapeutics Q3 2017 Earnings Report

Total Revenue
$2.39M
Previous year: $1.55M
+54.1%
EPS
-$0.62
Previous year: -$2.77
-77.6%
Gross Profit
-$15.5M
Previous year: -$10.5M
+47.2%
Cash and Equivalents
$254M
Previous year: $229M
+10.9%
Free Cash Flow
-$18.9M
Total Assets
$282M
Previous year: $279M
+1.3%

CRISPR Therapeutics

CRISPR Therapeutics